Page 3 - Scientific Library

CRISPR/Cas9 is relatively simple to implement, as the researcher fully controls the experimental design of the tools, from the sgRNA sequence to the Cas9 protein.

Rat liver tritosomes are hepatic lysosomes that have been loaded with Tyloxapol (Triton WR 1339), a non-ionic surfactant. Tyloxapol is taken up by hepatocytes through endocytosis and is trafficked to lysosomal

In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out of CD3 in human T-cells. The goal is to improve T-cell-based

Messenger RNAs - a promising class of new therapeutic biologics

As messenger RNAs (mRNAs) are easier to deliver into cells than plasmids or viral vectors, they are useful for non-dividing cells. Inversely

Sequence engineering and chemical modification of CAS9 mRNA

For transgenesis and

Sekisui XenoTech has just established a method for high Aldehyde Oxidase and Xanthine Oxidase activity in pooled Human liver test systems.

These new test systems (Pooled Human Liver S9 and cytosol) have

Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications

A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA enhance

Cell-based assays have become a classic way to monitor cells' reactions to a treatment or a specific stimulus. They involve a reporter construction and a detection system. The classic system is Firefly

Sekisui XenoTech have announced the addition of Rodent Hepatocytes to their patented CryostaX® product line.

The CryostaX® in vitro drug discovery and preclinical drug development test system is continuously

In this post, I'd like to introduce the Human liver Lysosomes developed by Sekisui-Xenotech, which have opened up a new era in catabolism models. Read on to learn more, and also to download a case study

Cell-based assays, screening for pathway activation or inhibition are classically done with promoter reporter clones expressing Firefly luciferase. Brighter, more stable, more sensitive, more convenient

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer primary